chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had a reaction to the vaccine and wanted to make sure you were aware. I had a very similar reaction to Kenalog about 4 years ago. Within minutes of receiving the vaccine, I started to feel like my body was racing a little. My foot started tapping and I felt hyperactive. At the end of my 15 minute wait time, I spoke to the physician that was in the room. I told him I was having a mild reaction and asked him if it was still okay for me to get the 2nd dose. He said yes, but he also took me over to another person to give me some Benadryl, just in case it got worse. They gave me 50mg of Benadryl and asked me to wait another 15 minutes to give it a little time to kick in. My reaction kept getting worse. I started itching all over and the hyperactive feeling became worse. She offered to use an epipen. I declined and  asked to wait another 15 minutes. At the 30 minute mark after taking the Benadryl, they called their EMT team because I continued to get worse. The team took me over to the ER. While they were pushing me there, my breathing started coming faster like I was panting. As if I had just gone for a run. Once I was in the ER, a physician saw me pretty quickly but it took a while until he came back to see me. I do not know how long it was. I would guess about 45 minutes to 1 hour. While waiting for the doctor the second time, it felt like my body started slowing down. Within 10 minutes, I felt like i had no energy left. I couldn't lift my arms. I was wide awake and could understand everything. But, all I could do was lay there. The ER doctor ordered oral Prednisone, IV Pepcid & IV Benadryl to be given immediately. He sent me home with prescriptions for the Prednisone and Pepcid since I already have Benadryl. He also recommended I not get the second dose and follow up with my PCP.
Administer expired vaccine to 450 patients, after the manufacture date of expiration.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine to 450 patients, after the manufacture date of expiration.) in a 61-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 070H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 08-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine to 450 patients, after the manufacture date of expiration.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine to 450 patients, after the manufacture date of expiration.) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. It was reported that dose administered after 30 day Use By Date or after manufacturer date of expiry. 173 doses were administered. On unknown date the vial was stored in the refrigerator. The vial did not undergo any temperature excursions. No treatment medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Live follow up received contains non significant information.
Until 12:00AM 04/03 - 5:00PM 04/04: Extreme migraine symptoms so severe, was debilitating. Could not walk, move, or see light without extreme pain. Was forced to take acetaminophen due to severity. Pain was severe enough to cause nausea and jaw soreness from clenching.   Patient suffers chronic tension headache and this was more severe than anything experienced - may have even been a cluster headache due to severity and location.
1 week after  I had the injection, the arm with the injection had an oval red rash.  It is itchy and warm to the touch. My primary care physician and I had a telehealth meeting.  She felt because it was 1 week after the injection I had cellulitis and put me on Cefadroxil for 10 days.  THe rash seem to be getting better however it was spreading on my arm. I went to a dermotologist who feel that it is due to the vaccine and gave me a cream Triamcinilone.  Today I notice that the rash has spread to my torso and I believe my unvaccinated arm ( it's itchy and starting to get red)
itchy; site is red; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE ERYTHEMA (site is red) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 30-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Jun-2021, the patient experienced VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE ERYTHEMA (site is red). At the time of the report, VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE ERYTHEMA (site is red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported.  No treatment medications provided by the reporter.
The patient was brought in for routine vaccinations on 11/29/2022. Pt was due for a Pediarix vaccine, it was administered on 11/29/2022 at 4:00 pm on the pts right thigh. The expiration date of the vaccines was on 11/28/2022.
Nausea, headaches, and ringing in ears.  sharp chest pain, dull heart pain, heart palpitations, heart racing at night, tingling/pins and needles in hands and feet, cold hands and feet, fatigue, body aches, shortness of breath when exercising
COVID TONGUE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced covid tongue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of covid tongue was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comments not required as per standard procedure as the case is considered non serious.
Patient received Covid-19 monovalent vaccine subcutaneously instead of intramuscularly.
6/5/2021- Outbreak of Shingles on lower left back, above waist. Preceded by 2 days of fatigue. Outbreak of rash, approx, 2"-3 "singular                            patch, lasted approx 2.5 to 3 weeks, and then resolved.  Pain and discomfort managed by Hydrocoritsone cream 1%
Patient came in for her 2nd dose of pfizer. She presented her vaccine card saying she received her first dose at costco 6/29/21. She received her vaccine, upon trying to batch fill the vaccine it rejected saying she received another type of covid shot. The insurance & pharmacy confirmed that she received Janssen on 3/8/21. Staff member at pharmacy said her temperature was checked and it was administer 3/8/21 @ 1:13pm lot # 1802076. Per Pharmacy Dept. confirmed that she received a dose of Pfizer from them 6/29/21 lot #EW0198, no time recorded. A voice message was left for the patient instructing her to call the pharmacy. We will inform the patient that there is no indication for 2 different types of covid shots.
General feeling of unwell; This is a spontaneous report received from a non-contactable non-health care professional. An unspecified age of female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Lot number: Not reported) via an unspecified route of administration on 16Mar2021 as a single dose for COVID-19 immunization. Patient medical history and concomitant medications were not reported. Patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Lot number: Not reported) via unspecified route of administration and anatomical site on 26Feb2021 as a single dose for COVID-19 immunization. On an unspecified date in 2021, patient experienced general feeling of unwell. The clinical outcome of the event general feeling of unwell was unknown.  No follow-up attempts are possible; information about lot number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information: Patient initials were updated; patient Country was added as United States; Lot unknown was removed from dosage regimens tab and BNT162B2 dose 1 was removed in product tab since captured it as historical vaccine already, event onset date added in structured field.
Awoke with itching and large redness at the vaccine shot site  Lasted for 2 days.  Applied Triamcinolone Acetonide Cream to site to relieve itching
From telephone contact with reporting nurse it was stated that a 20 year old male patient received a Menomune A/C/Y/W-135 vaccination on 31-Jul-2001. The patient developed a headache within 2 hours. Prolonged headache ranked a 9 on 1-10 scale. Patient also had diarrhea. Headache on 2-Aug-2001 rated a 4-5 on a scale of 1-10.   Ibuprofen and Tylenol did not work. No other shots were administered.  From additional correspondence received on 11-Sep-2001, it was reported that the patient recovered from this experience. Additional patient, vaccine, vaccine administrator and responsible physician information was also provided.
First dose made me get my period even though I am on continuous birth control and shouldn't get my period; I have been sick; Other vaccine same date vaccine date 02Mar2021; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 29 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 02Mar2021 13:30 (Lot number: EN6205) at the age of 29 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Primary immunodeficiency (CVID)" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Hydrocodone, reaction(s): "known allergies: Hydrocodone". The following information was reported: PRODUCT USE ISSUE (non-serious) with onset 02Mar2021, outcome "unknown", described as "Other vaccine same date vaccine date 02Mar2021"; MENSTRUAL DISORDER (non-serious) with onset 08Sep2021, outcome "not recovered", described as "First dose made me get my period even though I am on continuous birth control and shouldn't get my period"; ILLNESS (non-serious) with onset 08Sep2021, outcome "not recovered", described as "I have been sick". Therapeutic measures were not taken as a result of menstrual disorder, illness.  Additional Information: Each dose I have been sick for about 2 weeks. The patient did not received any other vaccine in four weeks. The patient had no Covid prior vaccination. The patient did not tested Covid post vaccination.  Follow-up attempts are completed. No further information is expected..
I experienced light headedness, blood pressure went up, heart rate went up, shaking, nausea.
Was fine the day of. Next day, work at approximately 10am with a sore arm. Headache grew progressively over the day, as did dizziness and feeling of sea sickness. As of approximately 8pm the following day too dizzy to drive or use stairs.
This spontaneous report was received from a registered nurse referring to an unspecified number of patients. Pertinent medical history, allergies and drug reactions were no reported. On 27-JUL-2016, the patient were vaccinated with an unspecified number of improperly stored doses of VAQTA lots # M021124 and M002268, expiry date 02-FEB-2018 and 20-SEP-2017 respectively. The doses and route of administration were not reported. No adverse effects were reported. Additional information has been requested.
Received dose from vial that had black particulates in previous syringe; Received dose from vial that had black particulates in previous syringe; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT QUALITY ISSUE (Received dose from vial that had black particulates in previous syringe) and POOR QUALITY PRODUCT ADMINISTERED (Received dose from vial that had black particulates in previous syringe) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012H21B) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Dec-2021, the patient experienced PRODUCT QUALITY ISSUE (Received dose from vial that had black particulates in previous syringe) and POOR QUALITY PRODUCT ADMINISTERED (Received dose from vial that had black particulates in previous syringe). On 01-Dec-2021, PRODUCT QUALITY ISSUE (Received dose from vial that had black particulates in previous syringe) and POOR QUALITY PRODUCT ADMINISTERED (Received dose from vial that had black particulates in previous syringe) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.
This spontaneous report was received from a registered nurse referring to a 11 year-old patient of unknown gender. The patient's pertinent medical history and concurrent conditions were not provided.    On 13-DEC-2017, the patient was vaccinated with an improperly stored dose of GARDASIL 9 lot # N004799, expiration date on 15-NOV-2019 or lot #N021475, expiration date on 21-JAN-2020, for prophylaxis (strength and route were not reported). The vaccine was stored at a temperature of 50°F for a time frame of 2 hours. No adverse effects neither previous temperature excursions for the improperly stored vaccine were reported. The call was because of a data logger. This case was one of several reports received from the same reporter. ; Sender's Comments: US-009507513-1801USA002510: US-009507513-1801USA002511: US-009507513-1801USA002512: US-009507513-1801USA002513: US-009507513-1801USA002515: US-009507513-1801USA002516: US-009507513-1801USA002517: US-009507513-1801USA002518: US-009507513-1712USA010085: US-009507513-1801USA002520: US-009507513-1801USA002521: US-009507513-1801USA002522: US-009507513-1801USA002509: US-009507513-1801USA002508: US-009507513-1801USA002514:
Pt complained of generalized weakness and dizziness.  No hx of htn, husband stated her normal systolic is 110  09:40 163/97 P 103 O2 97% FSBS 89 10:26 150/75 P 86 O2 96% Symptoms resolved  with juice and crackers but then recurred prior to discharge. She further c/o chest pain. Her care was transferred to EMS and she was transported to hospital
Extreme pain @ site of immunization, loss of mobility of right arm for 2 days, fever, sweating, nausea, could not sleep
w/in 5min of vax welt noted @ top of lt knee;rxn immed w/welt approx 5cm long by 1cm wide;pt observed & welt gone p/20min & observed x 25min longer;welts gone p/20min;
Feet continue to itch. Bottom of feet now peeling and feel raw. Hands are still swelling, but now are flaking off skin.
This spontaneous report has been received from a nurse concerning an unspecified number of patients of unknown age and gender. Concurrent conditions and pertinent medical history were not reported. On an unknown date, the patients were vaccinated with an improperly stored dose of VARIVAX, (Lot # L001325, exp. date on 13-JAN-2014) (strength, route of administration and dose were not provided). No adverse effects were reported. A product quality complaint was not involved. Additional information has been requested.
Vaccines administered - 3/26/2015. Fever, leg pain then rash developed 3/27/2015-3/29/2015. Admitted to hospital - rash is a leukocytoclastic vasculitis.
PATIENT HAD A SYNCOPAL REACTION ABOUT A MINUTE AFTER RECEIVING HER VACCINE.  PATIENT LOOKED PALE AND SWEATY.  911 WAS CALLED AND EMT EVALUATED PATIENT. PATIENT RECOVERED AND DID NOT REQUIRE ANY MEDICAL INTERVENTION. PATIENT LEFT WITH HER FRIENDS. PATIENT'S PCP WAS CONTACTED AND PCP INDICATED THAT THEY WOULD FOLLOW UP WITH PATIENT.
This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (has no hair, is completely bald with no hair in the head) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No specified medical history has been reported. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ALOPECIA (has no hair, is completely bald with no hair in the head). At the time of the report, ALOPECIA (has no hair, is completely bald with no hair in the head) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. Treatment information not provided. Concomitant medications were not provided. Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Follow up information received on 06-Jul-2021 contains no significant information.
redness, swelling, itching at the site. seen on telehealth and referred to PCP
Increases in F,O2 requiring change from nasal cannula O2 at trace to NCPAP. 35% O2 for 5 days post vax. Chest x-ray showed mild atelectasis. Temp of 36.7 to 37.3 Celsius while on Tylenol. 5 hours post vax O2 desaturations to 68%.
After administering the vaccine, pt complained of feeling lightheaded and passed out.  Pt responded immediately to smelling salts, was alert and oriented X 3, vital signs stable.  Pt reported she "forgot" to mention she has felt light headed after injections and her mother and sister have fainted just after injections.
A week later, I had a bad headache, sore throat, and coughed all night long. The next day, I woke up and I couldn't talk. I did a rapid COVID-19 test and it was negative. I went to urgent care and took a PCR test, and it was negative. When the results came back, they told me I had a staph infection. They prescribed a steroid and an antibiotic, but I don't recall the names of them. Friday afternoon my left eye got really swollen. I went to the emergency room and was diagnosed with Cellulitis. I followed up with my doctor on Monday and she verified that I had Cellulitis and a Staph infection. I am doing better now, but I am still coughing.
Post vaccination pt. reports dizziness, lightheadedness, and feeling anxious. Pt. transferred to med obs via stretcher accompanied by grandmother. Vital signs obtained and monitored, administered snack and water., pt. reports immediately feeling better after lying down and snack.  Pt. escorted back to exit accompanied by grandmother at 1335. vital signs as follows,  1320 LYING BP 130/76 HR 89 RESP 17 02 93% 1324 SITTING BP 117/75 HR 79 RESP 17 O2 SATS 95% 1330 STANDING BP 132/74 HR 86 RESP 17 O2 SATS 95%
Patient c/o SOB, no: LOC, fainting, rash, other symptoms. Treated with 50mg BENADRYL PO as per Dr's orders, symptoms did not return. Peak Flow Test (Spirometry) WNL. Patient has history of asthma.
Rash/hives started 1/31/2021.  Seen in clinic for this 2/2/2021 and Rx Prednisone and antihistamine and H2 blocker.  Then developed angioedema and went to ED on 2/3/2021.
I had the shingles vaccine (ZOSTAVAX) by my doctor. One hour later the pain in my right jaw was so intense it brought me to my knees. Then my right ear had an intense pain. Plus a severe headache (I never get headaches). I saw a nurse who said I was having a severe reaction. This continues for 7 more months although not as severe. I have had flu shots, pneumonia shot with no problems at all. Jan 2012 saw Dr. again with continuing pain particularly on right jaw - it felt like 20 root canals - great pain.
pt seen on 28MAY for red, itchy, swollen area on lt upper arm approx size 7" x 4", started 2 days p/vax spread to red area on lt upper chest, also itchy; tx w/DPH & follow w/family MD;
Patient is a 73 y.o. male patient with history of hypertension, now presented after a fall at home.  Patient became acutely hypoxic on 1/26/2023 morning.  Transferred to ICU where he developed asystole and passed away at 12:09 PM     Acute hypoxic respiratory failure PEA cardiac arrest COVID-19 infection became acutely hypoxic on 1/26/2023.  Stat chest x-ray, troponin, proBNP, lactic acid ordered Discussed with patient's wife on the phone and she confirmed that patient is DNR CCA/DNI, also reviewed docs in chart Patient developed PEA cardiac arrest at 12:09 PM on 1/26/2023   Fall, initial encounter Weakness and fatigue Failure to thrive CT head with no intracranial injury Scalp wound stapled in ER   Metastatic liver cancer Large liver mass at the hepatic hilum Cholangiocarcinoma Followed with Dr.   Acute kidney injury Likely prerenal from diarrhea Admission creatinine 1.7; baseline creatinine 0.85   Diarrhea on admission Rectal bleeding Acute infectious/inflammatory colitis of unclear etiology Cause unknown; suspect colitis of unclear etiology.  CT abdomen pelvis on admission showed nonspecific colonic wall thickening could reflect portal hypertensive colopathy, infectious/inflammatory colitis or incomplete distention   Diabetes  Hypertension   AAA Followed with Dr.    Anxiety and depression   Obesity BMI: 36.32.   History of tobacco abuse
symptoms: fever, congestion Admitted to hospital for scheduled knee replacement on 11/04/2022, slipped out of chair, required more surgery on 11/22/2022, tested positive for COVID-19 11/25/2022.
tested + for covid 1-9-22 at hospital.   Septic shock,  was supposedly transferred for further care.  I do not have any records following transfer.   Deceased 1-18-22.
Received third dose from vial refrigerated for more than 30 days; Product storage error; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received third dose from vial refrigerated for more than 30 days) and PRODUCT STORAGE ERROR (Product storage error) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received third dose from vial refrigerated for more than 30 days) and PRODUCT STORAGE ERROR (Product storage error). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received third dose from vial refrigerated for more than 30 days) and PRODUCT STORAGE ERROR (Product storage error) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided. Patient reported- The vaccine was defrosted in 30Aug2021 and it was administered on 01Oct2021.   This case was linked to MOD-2021-358921, MOD-2021-358773 (Patient Link).
Pressure in calves, burning, tingling, and sensation of circulation issues in some toes.  Light tingling in hands, Feels like nerve issues.